Literature DB >> 29102899

HDL functionality in type 1 diabetes.

Shiva Ganjali1, Geesje M Dallinga-Thie2, Luis E Simental-Mendía3, Maciej Banach4, Matteo Pirro5, Amirhossein Sahebkar6.   

Abstract

Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by absence of insulin secretion due to destruction of the pancreatic beta-cells. Patients with T1D exhibit an increased risk for cardiovascular disease (CVD) compared with non-diabetic subjects. It has been established that low concentration of high-density lipoprotein cholesterol (HDL-C), an independent risk marker of CVD, coincides with a reduced protective capacity against oxidative stress. However, conflicting results have been reported on the prevalence of low HDL-C levels in T1D. Interestingly, changes in composition and function of HDL particles (abnormal ratio of cholesteryl ester-to-triglyceride, reduction in the phospholipid content, reduced capacity to promote cholesterol efflux from macrophages, impaired anti-inflammatory and anti-oxidant activities) have been described in patients with T1D. Hence, exploring HDL function, even in the presence of normal HDL-C levels, might provide additional insight into the underlying pathophysiology associated with increased CV risk in T1D. In the current review, we will provide a detailed overview of the current evidence for a role of HDL function as independent risk factor for the development of CVD in T1D.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-inflammatory activity; Anti-oxidant activity; Cholesterol efflux; HDL functionality; Type 1 diabetes

Mesh:

Substances:

Year:  2017        PMID: 29102899     DOI: 10.1016/j.atherosclerosis.2017.10.018

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  20 in total

Review 1.  The early detection of atherosclerosis in type 1 diabetes: why, how and what to do about it.

Authors:  Alicia Jenkins; Andrzej Januszewski; David O'Neal
Journal:  Cardiovasc Endocrinol Metab       Date:  2019-02-13

2.  Albuminuria, the High-Density Lipoprotein Proteome, and Coronary Artery Calcification in Type 1 Diabetes Mellitus.

Authors:  Baohai Shao; Leila R Zelnick; Jake Wimberger; Jonathan Himmelfarb; John Brunzell; W Sean Davidson; Janet K Snell-Bergeon; Karin E Bornfeldt; Ian H de Boer; Jay W Heinecke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-05-16       Impact factor: 8.311

3.  HDL particle size is increased and HDL-cholesterol efflux is enhanced in type 1 diabetes: a cross-sectional study.

Authors:  Mohamad O Ahmed; Rachel E Byrne; Agnieszka Pazderska; Ricardo Segurado; Weili Guo; Anjuli Gunness; Isolda Frizelle; Mark Sherlock; Khalid S Ahmed; Anne McGowan; Kevin Moore; Gerard Boran; Fiona C McGillicuddy; James Gibney
Journal:  Diabetologia       Date:  2020-11-09       Impact factor: 10.122

Review 4.  Lipid management for cardiovascular risk reduction in type 1 diabetes.

Authors:  Shoshana Tell; Kristen J Nadeau; Robert H Eckel
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2020-08       Impact factor: 3.626

5.  Associations between epicardial adipose tissue, subclinical atherosclerosis and high-density lipoprotein composition in type 1 diabetes.

Authors:  Cristina Colom; David Viladés; Montserrat Pérez-Cuellar; Rubén Leta; Andrea Rivas-Urbina; Gemma Carreras; Jordi Ordóñez-Llanos; Antonio Pérez; Jose Luis Sánchez-Quesada
Journal:  Cardiovasc Diabetol       Date:  2018-12-07       Impact factor: 9.951

Review 6.  The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications.

Authors:  Nathan K P Wong; Stephen J Nicholls; Joanne T M Tan; Christina A Bursill
Journal:  Int J Mol Sci       Date:  2018-06-05       Impact factor: 5.923

Review 7.  High-Density Lipoprotein Function and Dysfunction in Health and Disease.

Authors:  Scott T Chiesa; Marietta Charakida
Journal:  Cardiovasc Drugs Ther       Date:  2019-04       Impact factor: 3.727

8.  Changes in the incidence and prevalence of type 1 and type 2 diabetes among 2 million children and adolescents in Hungary between 2001 and 2016 - a nationwide population-based study.

Authors:  László Barkai; Zoltán Kiss; György Rokszin; Zsolt Abonyi-Tóth; György Jermendy; István Wittmann; Péter Kempler
Journal:  Arch Med Sci       Date:  2019-10-07       Impact factor: 3.318

Review 9.  Cardiovascular disease in diabetes, beyond glucose.

Authors:  Robert H Eckel; Karin E Bornfeldt; Ira J Goldberg
Journal:  Cell Metab       Date:  2021-07-21       Impact factor: 31.373

10.  2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders.

Authors:  Bogdan Solnica; Grażyna Sygitowicz; Dariusz Sitkiewicz; Barbara Cybulska; Jacek Jóźwiak; Grażyna Odrowąż-Sypniewska; Maciej Banach
Journal:  Arch Med Sci       Date:  2020-03-02       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.